Eronyx has aggressive strategies and growth plans and aspires to collaborate with global pharmaceutical companies in the areas of:
-
- Development and manufacture of biologics in genetically modified organisms; starting with protein expression through clinical trials till eventual commercialization.
-
- Established strengths in development of drugs using Novel Drug Delivery Systems (NDDS) like microspheres, liposomes, micelles and emulsions.
-
- Expanding global presence for company’s current portfolio including orphan drugs with suitable product dossiers and Drug Master Files (DMF).
- Alliances for contract manufacturing, and joint ventures
- In-licensing of registered formulations (including nutritional) for Animal Health Business.
